Motor Function Measure News Today

Phase III trial finds that repurposed tamoxifen was safe but ineffective

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and...

Risdiplam appears to be an effective therapeutic option for patients with spinal muscular atrophy, leading to improved motor function, a study found.

Taysha Gene Therapies faces potential delisting of its shares—the latest in a series of setbacks that include scrapping a $75-million manufacturing facility in Durham, NC.

–– Roche, Genentech and partners embark on global prevalence research, trend-spotting with digital analysis, and telehealth initiatives to assess & address deterrents to brain health... | June 18, 2023

Data from pivotal SUNFISH study showed increases in motor function observed during the first year were maintained through the fourth year, while the overall rate of adverse events continued to decrease

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said that two-year data from the JEWELFISH study, which evaluated Evrysdi (risdiplam) ...

Investegate announcements from F. Hoffmann-La Roche Ltd, Positive new data for Roche’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)

Approval based on interim RAINBOWFISH data which show pre-symptomatic babies treated with Evrysdi for at least one year were able to sit, stand and walk...

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for...